Description
The National Institutes of Health (NIH) is seeking sources capable of providing proteomic biomarker testing services using the CNS panel 220 Argo NULISA platform for Government-furnished biospecimens. The purpose of this requirement is to identify biomarkers associated with underlying molecular changes in Alzheimer's Disease and Related Dementias (AD/ADRD) using well-characterized patient samples. The contractor will be required to perform high-throughput, quality-controlled proteomic analysis, including normalization, bridging controls, and quality control procedures, and provide deliverables such as biomarker readouts, QC data files, and raw sequencing data.
• The contractor must be capable of processing up to 8,970 samples per year.
• The contractor must maintain a throughput capacity of up to 2,400 samples per week.
• The contractor must provide quality control measures, including plate-level controls, external controls, and internal controls.
• The contractor must ensure the QC bridging cohort is matched to the relevant biofluid of interest.
• The contractor must use secure cloud-based delivery methods for data transmission.
Attached files
Contact
Linda Smith(Contracting Officer)